290650 — L&C Bio Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapMomentum Trap

Market Cap
KR₩512bn
Enterprise Value
KR₩622bn
Revenue
KR₩72bn

Annual income statement for L&C Bio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	32,973	45,677	52,572	65,927	72,093
Cost of Revenue
Gross Profit	19,558	28,450	26,992	33,856	35,729
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	25,649	32,503	43,048	60,173	69,569
Operating Profit	7,324	13,174	9,524	5,754	2,525
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	12,944	17,095	4,563	63,266	137,792
Provision for Income Taxes
Net Income After Taxes	12,149	15,580	5,692	48,859	143,237
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	10,813	13,814	4,544	48,361	141,064
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	10,813	13,814	4,544	51,826	142,649
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	494	618	197	2,176	5,733
Dividends per Share